ProgynyPGNY
PGNY
About: Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Employees: 680
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
645% more call options, than puts
Call options by funds: $4.34M | Put options by funds: $583K
41% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 34
3% more funds holding
Funds holding: 288 [Q1] → 297 (+9) [Q2]
1.72% more ownership
Funds ownership: 88.09% [Q1] → 89.81% (+1.72%) [Q2]
1% more capital invested
Capital invested by funds: $1.68B [Q1] → $1.69B (+$13.8M) [Q2]
5% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 111
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
1%
downside
Avg. target
$27
15%
upside
High target
$28
21%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Canaccord Genuity Richard Close | 1%downside $23 | Hold Maintained | 20 Aug 2025 |
Cantor Fitzgerald Sarah James | 21%upside $28 | Overweight Maintained | 8 Aug 2025 |
Truist Securities Jailendra Singh | 17%upside $27 | Hold Maintained | 17 Jul 2025 |
Leerink Partners Michael Cherny | 21%upside $28 | Outperform Upgraded | 8 Jul 2025 |
Financial journalist opinion
Based on 5 articles about PGNY published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q2 2025 Earnings Conference Call August 7, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Mark S. Livingston - Chief Financial Officer Michael Sturmer - President Peter Anevski - CEO & Director Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Larsen - BTIG, LLC, Research Division Jailendra P.
Positive
Zacks Investment Research
2 weeks ago
Progyny (PGNY) Tops Q2 Earnings and Revenue Estimates
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.43 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Progyny, Inc. Announces Second Quarter 2025 Results
Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement
Positive
Zacks Investment Research
3 weeks ago
Progyny (PGNY) Earnings Expected to Grow: Should You Buy?
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 weeks ago
New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage
Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings
Positive
Zacks Investment Research
1 month ago
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
GlobeNewsWire
1 month ago
Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA , maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights.
Positive
Zacks Investment Research
1 month ago
Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?
Progyny (PGNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance
Neutral
GlobeNewsWire
2 months ago
Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health
With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering
Charts implemented using Lightweight Charts™